ARKG vs VHT

Key Takeaways

• ARK Genomic Revolution ETF (ARKG) is an actively managed thematic fund targeting genomics and biotechnology innovations, while Vanguard Health Care ETF (VHT) is a passively managed broad-sector ETF tracking a comprehensive health care index.
• ARKG concentrates on fewer holdings (typically 30–60) with higher exposure to emerging biotech and genomics companies, whereas VHT holds over 400 stocks for broad diversification across pharmaceuticals, biotechnology, equipment, and services.
• Expense ratios differ significantly: ARKG charges 0.75% annually due to active management, compared to VHT’s low-cost 0.09% structure as a passive index fund.
• Sector exposure in ARKG emphasizes high-risk, high-reward genomics themes, while VHT provides balanced allocation across the entire health care sector with heavy weights in established large-cap names.
• Both ETFs operate within the health care space but serve distinct investor objectives—ARKG for thematic growth exposure and VHT for cost-efficient sector representation.
• Liquidity and structural features favor VHT for larger investors seeking stability, while ARKG appeals to those pursuing concentrated innovation-driven opportunities.

Introduction

Investors comparing ARK Genomic Revolution ETF (ARKG) and Vanguard Health Care ETF (VHT) gain insight into two distinct approaches to health care exposure. ARKG pursues active, thematic strategies centered on genomic advancements, while VHT delivers passive, broad-based tracking of the health care sector. These funds do not compete directly but offer alternative strategies for investors seeking sector participation: one emphasizes concentrated innovation bets, and the other provides diversified, low-cost access. In the current market environment, understanding their structural differences helps clarify positioning for growth-oriented versus stability-focused portfolios.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund from ARK Investment Management that seeks long-term capital appreciation by investing primarily in equity securities of companies benefiting from the genomics revolution. The fund typically holds 30–60 stocks, with top positions often including companies such as 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Guardant Health Inc (GH). Sector allocations concentrate heavily in health care and biotechnology, with secondary exposure to information technology and materials. ARKG carries an expense ratio of 0.75% and employs an active strategy without tracking a specific index, allowing manager discretion in security selection and weighting. Its distinguishing features include thematic focus on gene editing, molecular diagnostics, and bio-informatics, along with periodic rebalancing driven by fundamental research rather than mechanical rules.

Vanguard Health Care ETF (VHT) Overview

Vanguard Health Care ETF (VHT) is a passively managed fund that seeks to track the performance of the MSCI US Investable Market Health Care 25/50 Index. The ETF holds approximately 400–420 stocks across large-, mid-, and small-capitalization companies in the health care sector. Top holdings typically feature established names such as Eli Lilly and Co (LLY), Johnson & Johnson (JNJ), AbbVie Inc (ABBV), UnitedHealth Group Inc (UNH), and Merck & Co Inc (MRK). Sector allocations span pharmaceuticals, biotechnology, health care equipment, life sciences tools, and managed care services. VHT maintains a low expense ratio of 0.09% and uses a full-replication or sampling strategy to mirror its benchmark. Key structural characteristics include quarterly dividend distributions, broad diversification, and minimal turnover, resulting in a cost-efficient vehicle for comprehensive health care sector exposure.

Industry and Thematic Backdrop

The health care sector continues to navigate innovation cycles in biotechnology and genomics alongside steady demand for established pharmaceuticals and medical services. Macroeconomic drivers include aging populations, regulatory developments around drug pricing and approvals, and capital allocation toward precision medicine. Thematic catalysts center on advances in gene editing and diagnostics, while broader risks encompass interest rate sensitivity for growth-oriented companies and policy shifts affecting reimbursement. Both ETFs operate within this environment, with ARKG positioned for thematic disruption and VHT capturing the full spectrum of sector participants amid evolving capital flows and earnings cycles.

Performance and Positioning Comparison

In recent market cycles, ARK Genomic Revolution ETF (ARKG) has exhibited higher volatility tied to the performance of its concentrated genomics holdings and sensitivity to innovation news flow. Vanguard Health Care ETF (VHT) has delivered more stable returns through diversified exposure to large-cap health care leaders less affected by single-theme swings. Relative positioning shows ARKG benefiting from sector rotation toward high-growth biotech during favorable risk environments, while VHT maintains consistent representation across earnings cycles and macroeconomic shifts. Differences in expense structures and concentration levels further influence long-term compounding and risk-adjusted outcomes between the two funds.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Tickeron AI Verdict

Based on observable factors including cost efficiency, diversification profile, and structural stability, Tickeron’s AI would currently assign a higher probabilistic preference to Vanguard Health Care ETF (VHT). Its lower expense ratio, broad holdings, and passive replication methodology support more consistent sector exposure with reduced idiosyncratic risk compared to the concentrated thematic approach of ARK Genomic Revolution ETF (ARKG).

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations